An interventional study of Diagnosis strategy based on C. glabrata / krusei PCR in Candida, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic
Among 16 studies in Candidemia with a site in France — 1 open to participants now, 1 under way, 1 of them phase 3. Candidemia · France.
Among the 16 studies in Candidemia with a site in France, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is the only one with no phase, and was the 13th registered.
73 studies on the registry are indexed under Candidemia; 5 are open to participants now.
Browse Candidemia studies →1 of the 16 studies in Candidemia with a site in France is open now. Recruiting first, the newest first:
Basilea Pharmaceutica · Sites in France, United States, Argentina and 17 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 2 Candidemia studies recruiting now, 2 (100%) set no upper age limit and 0 (0%) stop at 75 or younger; 0 take children under 18; 0 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2022.
This study's enrollment of 48 is below the median of 63 across 44 interventional studies indexed under Candidemia.
Median enrollment 208 across the 10 interventional studies, 180 across the 6 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 16 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
University Hospital, Toulouse has 1 study filed under Candidemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Candidemia with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the implementation of a new technique for invasive candidiasis diagnosis by PCR. The main objective will be to evaluate the effect of this strategy on the time required to obtain results in patients from intensive care units with suspected systemic invasive candidiasis. This PCR method could allow an antifungal switch to be made earlier, limiting the appearance of resistance and reducing the cost of antifungals for healthcare facilities.
Invasive candidiasis is a serious infection caused by yeasts of the genus Candida sp. Their incidence is increasing, particularly in intensive care. The prognosis is severe and depends on the early initiation of adequate antifungal treatment. At present, the diagnosis of invasive candidiasis is difficult since blood culture, the reference technique, has major limitations due to its low sensitivity, as well as very long delays in obtaining results. As a consequence, suspected invasive candidiasis is often treated empirically with echinocandins, resulting in the development of resistance and extremely high costs for health care facilities. The switch to treatments such as fluconazole is often delayed, although this molecule is effective on most Candida species except C. krusei and glabrata and is much less expensive than echinocandins.
For these reasons, the present study developed faster and more efficient methods to diagnose Candida krusei and glabrata species, based on the detection of DNA in the blood by PCR, allowing an earlier switch from echinocandins to Fluconazole.
The patients included will be divided into 2 groups: one group of patients will benefit from a diagnostic strategy based on blood culture (reference technique for the detection of Candida) and another group of patients will benefit from a diagnostic strategy based on this new PCR technique. The main objective will be to evaluate the effect of the PCR strategy on the time to obtain results and on the switch of antifungal agents. After inclusion, patients will be followed up at day 14, day 28 until discharge (or 3 months if the patient is still hospitalised).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a blood culture-based diagnostic strategy
Patients from intensive care units with suspected invasive candidiasis initially treated with echinocandins and who benefited from a diagnostic strategy based on C. glabrata / krusei PCR
Diagnostic Test: Diagnosis strategy based on C. glabrata / krusei PCR
For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
Reporting delay
the time (in hours) required for the results to be returned in relation to the time of sample collection
Time frame: 14 days after blood sample taken
mortality at Day 28
Mortality rates will be taken 28 days after taking blood samples for Candida diagnosis in both groups
Time frame: 28 days after blood sample taken
Ran from May 2022 to primary completion in Apr 2025, 34 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →